ClinicalTrials.gg
CompletedNCT01915914Updated Oct 12, 2018Results posted

A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis

A Phase 4 interventional study of Fluticasone propionate in Skin Diseases, sponsored by GlaxoSmithKline. Completed at 4 sites in China. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2018-10-12.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Skin Diseases with a site in China — 2 open to participants now, 3 under way, 1 of them phase 3. Skin Diseases · China.

Enrollment
14th of 21
107 · median 216
Started
2013
with 1 other
Phase 4
Only one
of the 23
Registered
3rd of 23
by date
Lead sponsor
2 of 23
GlaxoSmithKline

Among the 23 studies in Skin Diseases with a site in China, this one is the 14th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2013, is the only one in phase 4, and was the 3rd registered.

Skin Diseases

497 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.

Browse Skin Diseases studies →

Open to participants now

2 of the 23 studies in Skin Diseases with a site in China are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Skin Diseases with a site in China, or all of them as a file.
02

Study summary

This is an open-label, randomized, comparative study, including 4 phases: SCREENING, ACUTE, MAINTENANCE and FOLLOW-UP.

Subjects will complete the SCREENING phase to check the eligibility within 7 days after they sign the written informed consent form. All eligible subjects will be enrolled in ACUTE phase to receive twice daily Fluticasone propionate (FP) 0.05% cream up to 4 weeks. The efficacy and safety in ACUTE phase will be assessed every 2 weeks up to 4 weeks or until Treatment Success which depends on which time point comes first. Then subject can get into the MAINTENANCE phase receiving either emollient twice daily plus FP 0.05% cream once daily twice a week (Group A), or emollient twice daily (Group B), by 1:1 randomization. The treatment duration in MAINTENANCE phase will be up to 20 weeks. The efficacy and safety in MAINTENANCE phase will be assessed every 4 weeks up to 20 weeks or until AD relapse that depends on which time point comes first. If subjects don't experience relapse during MAINTENANCE phase, subsequent FOLLOW-UP phase applying emollient twice daily won't be longer than another 12 weeks.

Total study duration is up to 37 weeks. All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient twice daily up to 12 weeks.

This study will enrol 120 subjects, and propose at least 80 subjects to be randomized.

Study Endpoints/Assessments:

Primary endpoint is to observe the median time to the first relapse of AD during MAINTENANCE phase.

Secondary endpoints are:

  1. Median time to the first relapse of AD during the whole study (including maintenance phase and follow-up phase.
  2. Numbers of recurrent patients at the end of MAINTENANCE phase;
  3. Numbers of recurrent patients at the end of FOLLOW-UP phase;
  4. The effective rates (proportion of "treatment success" patients) during ACUTE phase (V3, W-2±2days;V4, W0±2days )
  5. Evaluate the safety during the whole study duration (ACUTE phase, MAINTENANCE phase, FOLLOW-UP phase respectively);
  6. Evaluate visual skin assessment for signs of cutaneous atrophy, epidermal thickening / lichenification and abnormal pigmentation changes during the whole study duration (ACUTE phase, MAINTENANCE phase, FOLLOW-UP phase respectively);
  7. The change of Quality of Life (QoL) from baseline at the end of MAINTENANCE phase;
  8. The change of Quality of Life (QoL) from baseline at the end of FOLLOW-UP phase;
  9. Subjects' post-study evaluation to drugs.
Read the detailed description

Background Atopic dermatitis (AD) is a chronic relapsing skin disease caused by the intervention of plural unspecific stimulation or specific allergens accompanied with cutaneous physiologic dysfunction. AD is one of the most common skin diseases which effects up to 20% of Children and 1-3% of adults in most of countries of the world. The data from a Chinese epidemiologic research shows the prevalence rate of AD is 10.9%in school-age adolescent and 15.3% in preschool children in 2010.

Around 65% patients with AD develop the symptoms in the first year of life; and 90% patients develop the symptoms before 5 years of age. Onset of atopic dermatitis in adolescence or later is uncommon.

The objective of treatment in AD is to relief symptoms and reduces the cutaneous inflammation. Emollients as the mainstay of maintenance therapy are able to restore skin barrier function. Topical glucocorticoids recommended as first line treatment are important anti-inflammatory drugs to be used in AD, especially in the acute phase.

One of the most troublesome features of AD is its chronic relapsing nature suggesting the need for a long-term therapy of this disease. The common long-term treatment of AD is a reactive treatment approach based on the daily application of emollients accompanied by the application of topical glucocorticoids (TCS) or calcineurin inhibitors (TCI) 'as needed'. However, a new alternative treatment 'proactive therapy' has been proven its effective and well-tolerated to reduce AD relapse in clinical trials and recommended by guidelines.

This proactive therapy starts with an intensive topical anti-inflammatory therapy until all lesions have virtually cleared, followed by long-term, low-dose intermittent application of anti-inflammatory drugs to previous affected and now clinically healthy-looking skin combined with daily application of emollients to always unaffected areas.

Latest Chinese guideline of AD recommends the application of emollients or moisturizers in both the acute and maintenance phase, and intermittent application of topical corticosteroids with daily use of emollients and moisturizers as the first-line option of AD therapy.

However, the concept of 'proactive therapy' of AD has not been well accepted by Chinese dermatologists. In context, the studies demonstrated 'proactive therapy' efficacy has been done mainly in Caucasian subjects instead of in Chinese population. For this reason, there still exist unmet medical needs to generate data on combination use of fluticasone propionate with moisturizer in AD maintenance therapy in China.

Rationale Fluticasone propionate (FP) is a synthetic fluorinated corticosteroid of medium strength for the topical treatment of skin disease. The established glucocorticoids showed anti-inflammatory, anti-proliferative and immunosuppressive effects. FP has been demonstrated havinga moderate anti-inflammatory effect associated with good compliance among patients, a low incidence of cross-sensitivity reactions and a weak atrophogenicity.

FP does not show a significant effect on the hypothalamic pituitary axis (HPA), due to its lipophilicity, and its rapid hepatic biotransformation, reflecting a favourable ratio between topical and systemic activity. The results from a clinical trial with moderate to severe AD demonstrate that FP does not cause any major local side-effect. First-line therapy of AD in paediatric patients consist of the application of a mildly to moderately potent topical glucocorticoid combined with emollients . FP cream 0.05% has also been proven safe for the treatment of moderate to severe AD for up to 4 weeks in children 3 months of age and older.

More than one study has been demonstrated the efficacy and safety of FP 0.05% cream for proactive therapy of AD. A large multicentre study compared an intermittent dosing regimen of FP 0.05% cream (twice per week) with its drug-free vehicle in reducing the risk of relapse in adults and children (44% and 66% respectively) aged 3 months to 65 years with moderate or severe, but stabilized AD. Both regimens were added to regular daily emollient. The results showed patients receiving intermittent FP cream in the maintenance phase were 7.7 times (paediatric patients even 8.1 times) less likely to have an AD relapse compared with patients under vehicle cream. And the maintenance therapy with FP turned out to be safe and well-tolerated.

Subsequent similar large scale study was to compare the efficacy and safety of both FP 0.05% cream and 0.005% ointment in reducing the risk of relapses. The difference was that only patients aged 12-65 years with moderate to severe AD who were experiencing a flare were enrolled. FP 0.05% was more effective in reducing relapses than FP 0.005%: the former reducing the risk of relapses six fold and the latter two fold compared with emollient alone. Median time to relapse was 6 weeks for emollient alone compared with more than 16 weeks for additional FP. Both medications were well-tolerated with a low risk of local adverse effects.

First-line therapy of AD in paediatric patients consist of the application of a mildly to moderately potent topical glucocorticoid combined with emollients . Except for topical glucocorticoid, emollients are the basic treatment of AD, which have been recommended and emphasized by almost all the AD guidelines. PHYSIOGEL lotion, as a hypoallergenic emollient, contains physiological lipids, which mimics the structure and composition of the skin's protective lipid barrier with DMS (Dermal Membrane Structure) technique. PHYSIOGEL lotion provides immediate and long lasting moisture to prevent skin dryness, which has been recommended by dermatologists in AD adjunctive daily care. It is advised to apply a thin film of PHYSIOGEL lotion once to twice daily ideally for people of all ages with dry, sensitive and barrier dysfunction skin (including people suffering from AD).

In summary, a superiority of a proactive therapy with combination of FP and emollient over the drug-free vehicle or emollient alone has been demonstrated. Proactive therapy with FP prevented, delayed, and reduced the occurrence of exacerbations and AD relapses without any obvious safety concerns. Besides, PHYSIOGEL lotion, an emollient with physiological lipids and DMS technology, has good efficacy in repairing skin barrier. In this regard, it is possibly meaningful to demonstrate the efficacy and safety of a FP and PHYSIOGEL lotion combination in reducing AD relapse.

OBJECTIVE(S) This study is aimed to demonstrate the risk of AD relapse can be significantly reduced by extended intermittent dosing with Fluticasone propionate (FP) 0.05% cream in addition to regular emollient therapy (PHYSIOGEL lotion) in the maintenance treatment (20 weeks) of atopic dermatitis (AD) as compared with application of emollient alone.

The secondary objective is to evaluate the safety of FP 0.05% cream and emollient combination usage in AD maintenance treatment and determine the optimal treatment regimen in Chinese paediatric patients with AD.

Study Design This is an open-label, randomized, comparative study. The study includes 4 phases: SCREENING, ACUTE, MAINTENANCE and FOLLOW-UP.

After subjects sign the written informed consent form (Visit 1), they will enter the SCREENING phase to check the eligibility within 7 days before the 1st dose of FP 0.05% cream. During SCREENING phase, investigator will collect subjects' demographic data, medical history, Atopic Dermatitis' diagnosis and treatment history, concomitant medications. Investigator needs to assess AD Severity and conduct physical examination. Substance abuse will be evaluated. And pregnant test must be conducted to check for Women of childbearing potential (WOCBP).

-Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study (and for up to 6 weeks after the last dose of investigational product) in such a manner that the risk of pregnancy is minimized.

WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal.

Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or here their partner is sterile (e.g., vasectomy) should be considered to be of childbearing potential.

The Visit 2 will be occurred before the 1st dose of FP 0.05% cream. At Visit 2, investigator needs to evaluate Eczema Area, AD Severity and Visual Skin Assessment. Vital signs will be measured and recorded. Subjects need to complete the questionnaire of QoL under the investigator's instruction. Investigator must confirm subjects' eligibility for ACUTE phase after all of inclusion and exclusion criteria have been checked.

All subjects eligible for ACUTE phase will receive twice daily FP 0.05% cream. FP 0.05% cream will be applied to affected sites and any newly occurring AD sites.

The efficacy and safety in ACUTE phase will be assessed every 2 weeks up to 4 weeks or until Treatment Success dependent on which time point comes first. At each visit (Visit 3, W-2±2days; Visit 4, W0±2days) in ACUTE phase, investigator needs to assess Eczema Area, AD Severity, Visual Skin Assessment, and conduct physical examination, vital sign measurement. Randomization will be processed once investigator confirms the subject's eligibility for MAINTENANCE phase.

The day of randomization is D0 in MAINTENANCE phase. If patients achieve Treatment Success and meet the criteria of MAINTENANCE phase during the visit intervals of ACUTE phase, Visit 4 can be moved earlier than scheduled date. If the time of treatment success is within 2 weeks after Visit 2, the subject can enter Visit 4 directly by skipping Visit 3.

If patients don't achieve Treatment Success for 4-week FP 0.05% cream treatment, they will be discontinued study treatment and conduct End of Therapy Visit. The subjects eligible for MAINTENANCE phase will be 1:1 randomized to receive either emollient twice daily plus FP 0.05% cream once daily twice a week (Group A), or emollient twice daily (Group B). FP 0.05% cream will be applied to all healed sites and any newly occurring sites.

The efficacy and safety in MAINTENANCE phase will be assessed every 4 weeks up to 20 weeks or until AD relapse dependent on which time point comes first. At each visit (V5, W4±2days; V6, W8±2days; V7, W12±2days; V8,W16±2days;V9,W20±2days), Investigator needs to evaluate Eczema Area, AD Severity, Visual Skin Assessment, and conduct physical examination, vital sign measurement. The questionnaire of QoL needs to be completed by subjects at the end of maintenance phase.

In MAINTENANCE phase, once subjects experience AD Relapse, they will be discontinued study treatment and conduct End of Therapy Visit.

On the contrary, if subjects don't experience relapse during MAINTENANCE phase, all of them will enter FOLLOW-UP phase applying emollient twice daily.

The efficacy and safety in FOLLOW-UP phase will be assessed every 4 weeks up to 12 weeks or until AD relapse dependent on which time point comes first. At each visit (V10, W24±5days; V11, W28±5days; V12, W32±5days), investigator needs to evaluate Eczema Area, AD Severity, Visual Skin Assessment, and conduct physical examination, vital sign measurement.In FOLLOW-UP phase, once subjects experience AD relapse, they will be discontinued study treatment and conduct End of Therapy Visit.

At End of Therapy Visit, investigator needs to evaluate Eczema Area, AD Severity, Visual Skin Assessment, and conduct physical examination, vital sign measurement. Subjects need to complete the questionnaire of QoL and Subjects' post-study evaluation to drug.

Subjects need to conduct Early Withdrawal Visit once they meet Withdrawal Criteria. At Early Withdrawal Visit, investigator needs to evaluate Eczema Area, AD Severity, Visual Skin Assessment, and conduct physical examination, vital sign measurement. Subjects need to complete the questionnaire of QoL and Subjects' post-study evaluation to drug.

At each study visit, concomitant medications will be collected after receiving subject's written informed consent form, and AEs should be collected and documented after the first dose of FP. For the female subjects who has experienced menarche, urine pregnant test need to be done when subjects enter the study and be repeated at the end of the entire study. If the result is positive, the subject will quit from the study. The treatment compliance will be evaluated at each visit after the 1st dose of FP 0.05% cream.

Total study duration is up to 37 weeks.

03

Conditions studied

  • Skin Diseases

Browse trials for

04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Specific information regarding warnings, precautions, , adverse events, and other pertinent information on the GSK product or other study treatment that may impact subject eligibility is provided in the package insert of CUTIVATE and PHYSIOGEL Lotion.

Deviations from inclusion criteria are not allowed because they can potentially jeopardize the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol is essential. Subjects eligible for enrolment in the study must meet all of the following criteria:

  1. male or female patients age between 1 to 18 years old (including 1 year and excluding 18 years old);
  2. Diagnose atopic dermatitis according to criteria of Williams;
  3. Mild to moderate AD on the head/neck, trunk, upper limbs or lower limbs and PSGA scores 2-3;
  4. The must be signed before any study specific tests or procedures are initiated;

    Subjects eligible for enrolment in the MAINTENANCE phase of the study must meet all of the following criteria:

  5. Achieve treatment success after receiving Fluticasone propionate 0.05% cream twice daily up to 4 weeks in ACUTE phase

Exclusion criteria

Exclusion Criteria:

Deviations from exclusion criteria are not allowed because they can potentially jeopardize the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol is essential.

Subjects meeting any of the following criteria must not be enrolled in the study:

Acute phase:

  1. Dermatitis of only the face, feet or hands;
  2. The involved area has exceeded 10% of the whole body area;
  3. Diagnosed contact dermatitis at predilection sites of AD;
  4. Atrophy, telangiectasia, extensive scarring lesions in the area or areas to be treated;
  5. Had topical therapies including but not limit to calcineurin inhibitors (topical tacrolimus or topical pimecrolimus), , antihistamines within 14 days prior to screening;
  6. Has accepted nonsteroidal (eg cyclosporine, methotrexate), or ultraviolet light treatments including ultraviolet-A and ultraviolet-B, or systemic corticosteroids regardless administration by oral, intramuscular, or intravenous within 4 weeks prior to screening;
  7. Pregnant or breast-feeding. Women of (WOCBP) with a positive urine pregnancy test performed within 7 days before the start of treatment;
  8. Has immunocompromised disease (e.g. lymphoma, AIDS, Wiskott-Aldrich syndrome) or have a history of (including basal cell carcinoma, squamous cell carcinoma, melanoma);
  9. Has open skin infections (bacterial, viral or fungal) if at the application site;
  10. Has head lice or scabies;
  11. Present with clinical conditions other than AD that may interfere with the valuation (e.g. generalized erythrodema, toxicoderma, acne, Netherton's Syndrome, psoriasis);
  12. Require systemic therapy for the treatment of atopic dermatitis, or had systemic therapy including but not limit to antihistamines within 14 days prior to screening;
  13. Has accepted any experimental or drug or therapy within 6 weeks prior to screening;
  14. Has known to Fluticasone Propionate 0.05% cream, or PHYSIOGEL lotion, or relate drugs;
  15. Non-compliance with general medical treatment, or are known to miss appointments, or don't intend to comply with the protocol for the duration of the study;
  16. Drug abuse, mental dysfunction, or other factors limiting the subject's ability to cooperate fully with study-related procedures;
  17. Know to be unreliable or may be unable to complete the study;
  18. Any condition or prior/present treatment that would render the subject not eligible for the study;

    Maintenance phase:

  19. Accepted topic therapies other than Fluticasone propionate 0.05% cream and emollients during the ACUTE phase;
  20. Has active skin infection (bacterial, viral or fungal).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    fluticasone propionate

    To evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream (twice per week) in reducing the risk of relapse when added to regular daily moisturization using PHYSIOGEL Lotion in paediatric subjects with stabilized atopic dermatitis

    Drug: Fluticasone propionate

  • Active comparator
    physiogel

    To compare the efficacy and safety of fluticasone propionate 0.05% cream (twice per week) added to regular daily moisturization using Physiogel Lotion with Physiogel Lotion alone in paediatric subjects with stabilized atopic dermatitis

    Drug: Fluticasone propionate

Interventions

  • All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.

06

What researchers measure

Primary outcomes

  1. Time to the First Relapse of AD During the Maintenance Phase

    Time to the first relapse of AD is defined as the number of days from start of the FP treatment in Maintenance Phase until AD relapse. AD relapse is defined as participants with PSGA exacerbation score \>=2 (the six-point scale of PSGA score range from 0 to 5 where 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5=very severe) compared to PSGA score of treatment success during Acute Phase. Participants with treatment success are defined as participants with PSGA \<=1; and the improvement \>=2 compared to Baseline.

    Time frame: From the start of treatment up to Week 20 during the Maintenance Phase

Secondary outcomes

  1. Median Time to the First Relapse of AD During the Maintenance Phase and Follow-up Phase

    Median time to the first relapse of AD during the Maintenance Phase and Follow-up Phase is defined as the number of days from start of the FP treatment until AD relapse during the Maintenance Phase and Follow-up Phase. AD relapse is defined as participants with PSGA exacerbation score \>=2 (the six-point scale of PSGA score range from 0 to 5 where 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5=very severe) compared to PSGA score of treatment success during the Acute Phase.

    Time frame: From the start of treatment up to Week 32 during the Maintenance Phase and Follow-up Phase

  2. Numbers of Recurrent Participants at the End of the Maintenance Phase (Week 20)

    The number of participants with AD recurrent/relapse at the end of Maintenance Phase is presented. AD relapse is defined as participants with PSGA exacerbation score \>=2 (the six-point scale of PSGA: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5=very severe) compared to PSGA score of treatment success. Participants with treatment success is defined as participants with PSGA \<=1; and the improvement \>=2 compared to Baseline.

    Time frame: From Week 0 (or treatment success, if earlier) to Week 20

  3. Numbers of Recurrent Participants at the End of the Follow-up Phase (Week 32)

    The number of participants with AD recurrent/relapse at the end of the Follow-up Phase is presented. AD relapse is defined as participants with PSGA exacerbation score \>=2 (the six-point scale of PSGA: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5=very severe) compared to PSGA score of treatment success. Participants with treatment success is defined as participants with PSGA \<=1; and the improvement \>=2 compared to Baseline.

    Time frame: From Week 20 to Week 32

  4. Number of Participants With "Treatment Success" During the Acute Phase

    The number of participants with "treatment success" during the Acute Phase is presented. Participants with treatment success are defined as participants with PSGA \<=1; and the improvement \>=2 (the six-point scale of PSGA: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5=very severe) compared to Baseline in the Acute Phase of the study.

    Time frame: From the start of treatment up to Visit 4 (Week 0) or treatment success (depends on which time point comes first)

  5. Change From Baseline in Quality of Life (QoL) at the End of the Maintenance Phase

    Infant's Dermatitis Quality of Life Index (IDQOL) and Children's Dermatology Life Quality Index (CDLQI) were used to evaluate quality of life for participants of age between 1 to 16 years. IDQOL and CDLQI questionnaires were designed for infants (below the age of 4 years) and children (age 4 to age 16) with atopic dermatitis, respectively. The IDQOL and CDLQI were calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score in each questionnaire, the more quality of life is impaired. The change from Baseline in the QoL score is based on each questionnaire at the end of the Maintenance Phase and is calculated as the score at the end of the Maintenance Phase minus the Baseline score. Baseline is defined as QoL scores obtained at Visit 4 (end of Acute Phase). A QOL is equal to IDQOL if the age of a participant is \< 4 years and it is equal to CDLQI if the age of a participant is between 4 and 16 years.

    Time frame: Baseline and Week 20

  6. Change From Baseline in QoL at the End of the Follow-up Phase

    Infant's IDQOL and Children's CDLQI were used to evaluate quality of life for participants of age between 1 to 16 years. IDQOL and CDLQI questionnaires were designed for infants (below the age of 4 years) and children (age 4 to age 16) with AD, respectively. The IDQOL and CDLQI were calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score in each questionnaire, the more quality of life is impaired. The change from Baseline in QoL score is based on each questionnaire at the end of the Follow-up Phase and is calculated as the score at the end of the Follow-up Phase minus the Baseline score. Baseline is defined as QoL scores obtained at Visit 4 (end of Acute Phase). A QOL is equal to IDQOL if the age of a participant is \< 4 years and it is equal to CDLQI if the age of a participant is between 4 and 16 years.

    Time frame: Baseline and Week 32

  7. Number of Participants With Post-study Assessment of Skin Emollients Using Questionnaire

    Participants from each group completed the post-study questionnaire to rate the skin emollients (gel, lotion, cream, ointment, solution and foam) used in the past based on their experience. Participants rated skin emollients on a 5-point scale (5= "liked the best", 4= "second best", 3= "third best", 2= "fourth best, 1= "liked the least", N/A=Does not apply to me).

    Time frame: At early withdrawal or end of the therapy visit (up to Week 32)

  8. Number of Participants With Post-study Assessment of Lotion Qualities (1) Using Questionnaire

    Participants from each group completed the post-study questionnaire to rate the qualities of the lotion as compared with other skin emollients used in the past based on their experience. Each participant was asked the following Questions (Q). Q 1: This product is easier to use than other skin emollients; Q 2: When I apply this product I am able to start my daily activities quicker than with other skin emollients; Q 3: This product leaves my skin feeling softer than other skin emollients; Q 4: I am able to apply this product to larger body surface areas than other skin emollients; Q 5: This product disappears into my skin quicker than when I apply other skin emollients. Participants rated the qualities of the lotion based on a 5 point scale (5= "Strongly Agree", 4= "Agree", 3= "Neutral", 2= "Disagree", 1= "Strongly Disagree" N/A=Does not apply to me). Participant's rating for each question were summarized.

    Time frame: At early withdrawal or end of the therapy visit (up to Week 32)

  9. Number of Participants With Post-study Assessment of Lotion Qualities (2) Using Questionnaire

    Participants from each group completed the post-study questionnaire to rate the qualities of the lotion as compared with other skin emollients used in the past based on their experience. Each participant was asked the following Questions (Q). Q 1: It leaves my skin feeling soft and smooth; Q 2: There is nothing left on my skin; Q 3: Does not feel greasy; Q 4: Disappears into my skin quickly after I put it on; Q 5: Easy to apply; Q 6: Fragrance-free; Q 7: Spreadability; Q 8: Lack of stickiness. Participants rated the qualities of the lotion based on a 5 point scale (5= "Strongly Agree", 4= "Agree", 3= "Neutral", 2= "Disagree", 1= "Strongly Disagree" N/A=Does not apply to me). Participant's rating for each question were summarized.

    Time frame: At early withdrawal or end of the therapy visit (up to Week 32)

  10. Change From Baseline in Cutaneous Atrophy Sign Score, Epidermal Thickening /Lichenification Sign Score and Abnormal Pigmentation Score Using Visual Analogue Scale (VAS) at the End of the Acute Phase

    Investigator evaluated and scored the signs of cutaneous atrophy (CA), epidermal thickening/lichenification (ET/L) and abnormal pigmentation (AP) using Visual Analogue Scale (ranging from 0 to 10, higher values represent a worse outcome) based on their subjective judgment. The change from Baseline in each signs (Cutaneous atrophy, epidermal thickening / lichenification and abnormal pigmentation) score at the end of the Acute Phase (Visit 4 \[Week 0 or treatment success, depend on which time point comes first) ±2day\]) and is calculated as the score at Visit 4 minus the Baseline score. Baseline is defined as the VAS score for each sign obtained before the first dose of study drug in the Acute Phase of the study (Visit 2). Summation of the VAS scores for each sign (CA, ET/L and AP) was done to calculate the Total VAS score (ranging from 0 to 30, higher values represent a worse outcome) at Visit 4 of the Acute Phase of the study.

    Time frame: From the start of treatment up to Visit 4 (Week 0) or treatment success (depends on which time point comes first)

  11. Change From Baseline in Cutaneous Atrophy Sign Score, Epidermal Thickening /Lichenification Sign Score and Abnormal Pigmentation Score Using Visual Analogue Scale (VAS) at the End of the Maintenance Phase and Follow-up Phase

    Investigator evaluated and scored the signs of cutaneous atrophy (CA), epidermal thickening/lichenification (ET/L) and abnormal pigmentation (AP) using the Visual Analogue Scale (ranging from 0 to 10, higher values represent a worse outcome) based on their subjective judgment. The change from Baseline in each sign (Cutaneous atrophy, epidermal thickening / lichenification and abnormal pigmentation) score at the end of the Maintenance Phase and Follow-up Phase and is calculated as the score at the end of the Maintenance and Follow-up Phase minus the Baseline score. Baseline is defined as VAS score for each sign obtained at Visit 4 (end of Acute Phase). Summation of VAS scores for each sign (CA, ET/L and AP) was done to calculate the Total VAS score (ranging from 0 to 30, higher values represent a worse outcome) at the Maintenance and Follow-up phase of study. The missing value was imputed using last-observation-carry-forward (LOCF) method.

    Time frame: Baseline, Week 20 and Week 32

07

Results

Posted Dec 23, 2015

Participant flow

Number of enrolled participants n=123 in Acute Phase and n=107 in Maintenance Phase (ITT Population).

Acute Phase
Participant flow — Acute Phase
MilestoneFP 0.05% CreamEmollient Plus FP 0.05% CreamEmollientFollow-up: Emollient
Started123000
Completed-not entered maintenance phase4000
Completed111000
Not completed12000
Withdrew: Withdrawal by subject4000
Withdrew: Lost to follow-up4000
Withdrew: Physician decision1000
Withdrew: Accepted other topic therapies1000
Withdrew: Not achieved "treatment success"1000
Withdrew: Missing1000
Maintenance Phase
Participant flow — Maintenance Phase
MilestoneFP 0.05% CreamEmollient Plus FP 0.05% CreamEmollientFollow-up: Emollient
Started054530
Completed048510
Not completed0620
Withdrew: Withdrawal by subject0110
Withdrew: Lost to follow-up0410
Withdrew: Missing0100
Follow-up Phase
Participant flow — Follow-up Phase
MilestoneFP 0.05% CreamEmollient Plus FP 0.05% CreamEmollientFollow-up: Emollient
Started00066
Completed00064
Not completed0002
Withdrew: Withdrawal by subject0001
Withdrew: Physician decision0001

Outcome measures

PrimaryTime to the First Relapse of AD During the Maintenance Phase

Time to the first relapse of AD is defined as the number of days from start of the FP treatment in Maintenance Phase until AD relapse. AD relapse is defined as participants with PSGA exacerbation score \>=2 (the six-point scale of PSGA score range from 0 to 5 where 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5=very severe) compared to PSGA score of treatment success during Acute Phase. Participants with treatment success are defined as participants with PSGA \<=1; and the improvement \>=2 compared to Baseline.

Time frame:
From the start of treatment up to Week 20 during the Maintenance Phase
Reported as:
Median · Days
Time to the First Relapse of AD During the Maintenance Phase
DaysEmollient Plus FP 0.05% CreamEmollient
Time to the First Relapse of AD During the Maintenance PhaseNA (NA to NA)142.0 (50.0 to 150.0)
Statistical analysis
  • Emollient Plus FP 0.05% Cream vs Emollient · Log Rank · p = <0.0001 · Hazard ratio (hr): 13.4993 · 95% CI 4.1113 to 44.3250
SecondaryMedian Time to the First Relapse of AD During the Maintenance Phase and Follow-up Phase

Median time to the first relapse of AD during the Maintenance Phase and Follow-up Phase is defined as the number of days from start of the FP treatment until AD relapse during the Maintenance Phase and Follow-up Phase. AD relapse is defined as participants with PSGA exacerbation score \>=2 (the six-point scale of PSGA score range from 0 to 5 where 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5=very severe) compared to PSGA score of treatment success during the Acute Phase.

Time frame:
From the start of treatment up to Week 32 during the Maintenance Phase and Follow-up Phase
Reported as:
Median · Days
Median Time to the First Relapse of AD During the Maintenance Phase and Follow-up Phase
DaysEmollient Plus FP 0.05% CreamEmollient
Median Time to the First Relapse of AD During the Maintenance Phase and Follow-up PhaseNA (NA to NA)142.0 (50.0 to NA)
Statistical analysis
  • Emollient Plus FP 0.05% Cream vs Emollient · Log Rank · p = <0.0001 · Hazard ratio (hr): 4.9524 · 95% CI 2.4258 to 10.1105
SecondaryNumbers of Recurrent Participants at the End of the Maintenance Phase (Week 20)

The number of participants with AD recurrent/relapse at the end of Maintenance Phase is presented. AD relapse is defined as participants with PSGA exacerbation score \>=2 (the six-point scale of PSGA: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5=very severe) compared to PSGA score of treatment success. Participants with treatment success is defined as participants with PSGA \<=1; and the improvement \>=2 compared to Baseline.

Time frame:
From Week 0 (or treatment success, if earlier) to Week 20
Reported as:
Number · Participants
Numbers of Recurrent Participants at the End of the Maintenance Phase (Week 20)
ParticipantsEmollient Plus FP 0.05% CreamEmollient
Numbers of Recurrent Participants at the End of the Maintenance Phase (Week 20)330
Statistical analysis
  • Emollient Plus FP 0.05% Cream vs Emollient · Fisher Exact · p = <0.0001
SecondaryNumbers of Recurrent Participants at the End of the Follow-up Phase (Week 32)

The number of participants with AD recurrent/relapse at the end of the Follow-up Phase is presented. AD relapse is defined as participants with PSGA exacerbation score \>=2 (the six-point scale of PSGA: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5=very severe) compared to PSGA score of treatment success. Participants with treatment success is defined as participants with PSGA \<=1; and the improvement \>=2 compared to Baseline.

Time frame:
From Week 20 to Week 32
Reported as:
Number · Participants
Numbers of Recurrent Participants at the End of the Follow-up Phase (Week 32)
ParticipantsEmollient Plus FP 0.05% CreamEmollient
Numbers of Recurrent Participants at the End of the Follow-up Phase (Week 32)1032
Statistical analysis
  • Emollient Plus FP 0.05% Cream vs Emollient · Chi-squared · p = <0.0001
SecondaryNumber of Participants With "Treatment Success" During the Acute Phase

The number of participants with "treatment success" during the Acute Phase is presented. Participants with treatment success are defined as participants with PSGA \<=1; and the improvement \>=2 (the six-point scale of PSGA: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5=very severe) compared to Baseline in the Acute Phase of the study.

Time frame:
From the start of treatment up to Visit 4 (Week 0) or treatment success (depends on which time point comes first)
Reported as:
Number · Participants
Number of Participants With "Treatment Success" During the Acute Phase
ParticipantsFP 0.05% Cream
Number of Participants With "Treatment Success" During the Acute Phase107
SecondaryChange From Baseline in Quality of Life (QoL) at the End of the Maintenance Phase

Infant's Dermatitis Quality of Life Index (IDQOL) and Children's Dermatology Life Quality Index (CDLQI) were used to evaluate quality of life for participants of age between 1 to 16 years. IDQOL and CDLQI questionnaires were designed for infants (below the age of 4 years) and children (age 4 to age 16) with atopic dermatitis, respectively. The IDQOL and CDLQI were calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score in each questionnaire, the more quality of life is impaired. The change from Baseline in the QoL score is based on each questionnaire at the end of the Maintenance Phase and is calculated as the score at the end of the Maintenance Phase minus the Baseline score. Baseline is defined as QoL scores obtained at Visit 4 (end of Acute Phase). A QOL is equal to IDQOL if the age of a participant is \< 4 years and it is equal to CDLQI if the age of a participant is between 4 and 16 years.

Time frame:
Baseline and Week 20
Reported as:
Mean · Scores on a scale
Change From Baseline in Quality of Life (QoL) at the End of the Maintenance Phase
Scores on a scaleEmollient Plus FP 0.05% CreamEmollient
Change From Baseline in Quality of Life (QoL) at the End of the Maintenance Phase-0.4 ± 4.402.2 ± 4.68
Statistical analysis
  • Emollient Plus FP 0.05% Cream vs Emollient · ANCOVA · p = <0.0001
SecondaryChange From Baseline in QoL at the End of the Follow-up Phase

Infant's IDQOL and Children's CDLQI were used to evaluate quality of life for participants of age between 1 to 16 years. IDQOL and CDLQI questionnaires were designed for infants (below the age of 4 years) and children (age 4 to age 16) with AD, respectively. The IDQOL and CDLQI were calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score in each questionnaire, the more quality of life is impaired. The change from Baseline in QoL score is based on each questionnaire at the end of the Follow-up Phase and is calculated as the score at the end of the Follow-up Phase minus the Baseline score. Baseline is defined as QoL scores obtained at Visit 4 (end of Acute Phase). A QOL is equal to IDQOL if the age of a participant is \< 4 years and it is equal to CDLQI if the age of a participant is between 4 and 16 years.

Time frame:
Baseline and Week 32
Reported as:
Mean · Scores on a scale
Change From Baseline in QoL at the End of the Follow-up Phase
Scores on a scaleEmollient Plus FP 0.05% CreamEmollient
Change From Baseline in QoL at the End of the Follow-up Phase0.0 ± 4.972.2 ± 5.10
Statistical analysis
  • Emollient Plus FP 0.05% Cream vs Emollient · ANCOVA · p = <0.0001
SecondaryNumber of Participants With Post-study Assessment of Skin Emollients Using Questionnaire

Participants from each group completed the post-study questionnaire to rate the skin emollients (gel, lotion, cream, ointment, solution and foam) used in the past based on their experience. Participants rated skin emollients on a 5-point scale (5= "liked the best", 4= "second best", 3= "third best", 2= "fourth best, 1= "liked the least", N/A=Does not apply to me).

Time frame:
At early withdrawal or end of the therapy visit (up to Week 32)
Reported as:
Number · Participants
Number of Participants With Post-study Assessment of Skin Emollients Using Questionnaire
ParticipantsEmollient Plus FP 0.05% CreamEmollient
Gel, 121
Gel, 221
Gel, 322
Gel, 422
Gel, 510
Gel, N/A3944
Lotion, 111
Lotion, 201
Lotion, 372
Lotion, 4812
Lotion, 52726
Lotion, N/A58
Cream, 110
Cream, 212
Cream, 372
Cream, 41218
Cream, 565
Cream, N/A2123
Ointment, 113
Ointment, 273
Ointment, 3510
Ointment, 433
Ointment, 51011
Ointment, N/A2220
Solution, 101
Solution, 210
Solution, 345
Solution, 442
Solution, 510
Solution, N/A3842
Foam, 142
Foam, 211
Foam, 310
Foam, 400
Foam, 500
Foam, N/A4247
SecondaryNumber of Participants With Post-study Assessment of Lotion Qualities (1) Using Questionnaire

Participants from each group completed the post-study questionnaire to rate the qualities of the lotion as compared with other skin emollients used in the past based on their experience. Each participant was asked the following Questions (Q). Q 1: This product is easier to use than other skin emollients; Q 2: When I apply this product I am able to start my daily activities quicker than with other skin emollients; Q 3: This product leaves my skin feeling softer than other skin emollients; Q 4: I am able to apply this product to larger body surface areas than other skin emollients; Q 5: This product disappears into my skin quicker than when I apply other skin emollients. Participants rated the qualities of the lotion based on a 5 point scale (5= "Strongly Agree", 4= "Agree", 3= "Neutral", 2= "Disagree", 1= "Strongly Disagree" N/A=Does not apply to me). Participant's rating for each question were summarized.

Time frame:
At early withdrawal or end of the therapy visit (up to Week 32)
Reported as:
Number · Participants
Number of Participants With Post-study Assessment of Lotion Qualities (1) Using Questionnaire
ParticipantsEmollient Plus FP 0.05% CreamEmollient
Q 1, 100
Q 1, 204
Q 1, 3513
Q 1, 4 or 53929
Q 1, N/A44
Q 2, 101
Q 2, 212
Q 2, 3513
Q 2, 4 or 53829
Q 2, N/A45
Q 3, 100
Q 3, 213
Q 3, 349
Q 3, 4 or 53934
Q 3, N/A44
Q 4, 101
Q 4, 201
Q 4, 367
Q 4, 4 or 53837
Q 4, N/A44
Q 5, 102
Q 5, 202
Q 5, 3610
Q 5, 4 or 53832
Q 5, N/A44
SecondaryNumber of Participants With Post-study Assessment of Lotion Qualities (2) Using Questionnaire

Participants from each group completed the post-study questionnaire to rate the qualities of the lotion as compared with other skin emollients used in the past based on their experience. Each participant was asked the following Questions (Q). Q 1: It leaves my skin feeling soft and smooth; Q 2: There is nothing left on my skin; Q 3: Does not feel greasy; Q 4: Disappears into my skin quickly after I put it on; Q 5: Easy to apply; Q 6: Fragrance-free; Q 7: Spreadability; Q 8: Lack of stickiness. Participants rated the qualities of the lotion based on a 5 point scale (5= "Strongly Agree", 4= "Agree", 3= "Neutral", 2= "Disagree", 1= "Strongly Disagree" N/A=Does not apply to me). Participant's rating for each question were summarized.

Time frame:
At early withdrawal or end of the therapy visit (up to Week 32)
Reported as:
Number · Participants
Number of Participants With Post-study Assessment of Lotion Qualities (2) Using Questionnaire
ParticipantsEmollient Plus FP 0.05% CreamEmollient
Q 1, 100
Q 1, 211
Q 1, 3311
Q 1, 4 or 54437
Q 1, N/A01
Q 2, 100
Q 2, 234
Q 2, 318
Q 2, 4 or 54438
Q 2, N/A00
Q 3, 102
Q 3, 233
Q 3, 3210
Q 3, 4 or 54335
Q 3, N/A00
Q 4, 102
Q 4, 213
Q 4, 327
Q 4, 4 or 54538
Q 4, N/A00
Q 5, 102
Q 5, 211
Q 5, 325
Q 5, 4 or 54542
Q 5, N/A00
Q 6, 100
Q 6, 200
Q 6, 315
Q 6, 4 or 54745
Q 6, N/A00
Q 7, 100
Q 7, 210
Q 7, 329
Q 7, 4 or 54541
Q 7, N/A00
Q 8, 102
Q 8, 233
Q 8, 3210
Q 8, 4 or 54335
Q 8, N/A00
SecondaryChange From Baseline in Cutaneous Atrophy Sign Score, Epidermal Thickening /Lichenification Sign Score and Abnormal Pigmentation Score Using Visual Analogue Scale (VAS) at the End of the Acute Phase

Investigator evaluated and scored the signs of cutaneous atrophy (CA), epidermal thickening/lichenification (ET/L) and abnormal pigmentation (AP) using Visual Analogue Scale (ranging from 0 to 10, higher values represent a worse outcome) based on their subjective judgment. The change from Baseline in each signs (Cutaneous atrophy, epidermal thickening / lichenification and abnormal pigmentation) score at the end of the Acute Phase (Visit 4 \[Week 0 or treatment success, depend on which time point comes first) ±2day\]) and is calculated as the score at Visit 4 minus the Baseline score. Baseline is defined as the VAS score for each sign obtained before the first dose of study drug in the Acute Phase of the study (Visit 2). Summation of the VAS scores for each sign (CA, ET/L and AP) was done to calculate the Total VAS score (ranging from 0 to 30, higher values represent a worse outcome) at Visit 4 of the Acute Phase of the study.

Time frame:
From the start of treatment up to Visit 4 (Week 0) or treatment success (depends on which time point comes first)
Reported as:
Mean · Scores on a scale
Change From Baseline in Cutaneous Atrophy Sign Score, Epidermal Thickening /Lichenification Sign Score and Abnormal Pigmentation Score Using Visual Analogue Scale (VAS) at the End of the Acute Phase
Scores on a scaleFP 0.05% Cream
Visit 4, CA-0.3 ± 1.12
Visit 4, ET/L-1.9 ± 1.57
Visit 4, AP-0.7 ± 1.47
Visit 4, Total VAS Score-2.9 ± 3.14
SecondaryChange From Baseline in Cutaneous Atrophy Sign Score, Epidermal Thickening /Lichenification Sign Score and Abnormal Pigmentation Score Using Visual Analogue Scale (VAS) at the End of the Maintenance Phase and Follow-up Phase

Investigator evaluated and scored the signs of cutaneous atrophy (CA), epidermal thickening/lichenification (ET/L) and abnormal pigmentation (AP) using the Visual Analogue Scale (ranging from 0 to 10, higher values represent a worse outcome) based on their subjective judgment. The change from Baseline in each sign (Cutaneous atrophy, epidermal thickening / lichenification and abnormal pigmentation) score at the end of the Maintenance Phase and Follow-up Phase and is calculated as the score at the end of the Maintenance and Follow-up Phase minus the Baseline score. Baseline is defined as VAS score for each sign obtained at Visit 4 (end of Acute Phase). Summation of VAS scores for each sign (CA, ET/L and AP) was done to calculate the Total VAS score (ranging from 0 to 30, higher values represent a worse outcome) at the Maintenance and Follow-up phase of study. The missing value was imputed using last-observation-carry-forward (LOCF) method.

Time frame:
Baseline, Week 20 and Week 32
Reported as:
Mean · Scores on a scale
Change From Baseline in Cutaneous Atrophy Sign Score, Epidermal Thickening /Lichenification Sign Score and Abnormal Pigmentation Score Using Visual Analogue Scale (VAS) at the End of the Maintenance Phase and Follow-up Phase
Scores on a scaleEmollient Plus FP 0.05% CreamEmollient
Week 20, CA-0.1 ± 0.44-0.2 ± 1.01
Week 20, ET/L-0.4 ± 1.490.5 ± 1.51
Week 20, AP-0.4 ± 1.420.0 ± 1.32
Week 32, CA-0.1 ± 0.58-0.2 ± 1.03
Week 32, ET/L0.1 ± 1.190.6 ± 1.53
Week 32, AP-0.3 ± 1.230.0 ± 1.35
Week 20, Total VAS Score-0.9 ± 2.610.3 ± 2.75
Week 32, Total VAS Score-0.3 ± 2.090.4 ± 2.82
Statistical analysis
  • Emollient Plus FP 0.05% Cream vs Emollient · Wilcoxon (Mann-Whitney) · p = 0.7010 (Week 20, CA)
  • Emollient Plus FP 0.05% Cream vs Emollient · Wilcoxon (Mann-Whitney) · p = 0.0042 (Week 20, ET/L)
  • Emollient Plus FP 0.05% Cream vs Emollient · Wilcoxon (Mann-Whitney) · p = 0.0810 (Week 20, AP)
  • Emollient Plus FP 0.05% Cream vs Emollient · Wilcoxon (Mann-Whitney) · p = 0.2799 (Week 32, CA)
  • Emollient Plus FP 0.05% Cream vs Emollient · Wilcoxon (Mann-Whitney) · p = 0.1375 (Week 32, ET/L)
  • Emollient Plus FP 0.05% Cream vs Emollient · Wilcoxon (Mann-Whitney) · p = 0.1100 (Week 32, AP)
  • Emollient Plus FP 0.05% Cream vs Emollient · Wilcoxon (Mann-Whitney) · p = 0.0394 (Week 20, Total VAS Score)
  • Emollient Plus FP 0.05% Cream vs Emollient · Wilcoxon (Mann-Whitney) · p = 0.2237 (Week 32, Total VAS Score)

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study drug until follow-up (last dose of study treatment (emollient), up to Week 32).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FP 0.05% Cream—0/116 (0%)4/116 (3.4%)
Emollient Plus FP 0.05% Cream—2/53 (3.8%)9/53 (17%)
Emollient—0/53 (0%)9/53 (17%)
Follow-up: Emollient—0/66 (0%)11/66 (16.7%)
Most frequent serious events
Most frequent serious events
EventFP 0.05% CreamEmollient Plus FP 0.05% CreamEmollientFollow-up: Emollient
BronchitisInfections and infestations0/1161/530/530/66
Hand-foot-and-mouth diseaseInfections and infestations0/1161/530/530/66
Infectious mononucleosisInfections and infestations0/1161/530/530/66
Mycoplasma infectionInfections and infestations0/1161/530/530/66
Most frequent other events
Showing 10 of 21
Most frequent other events
EventFP 0.05% CreamEmollient Plus FP 0.05% CreamEmollientFollow-up: Emollient
PyrexiaGeneral disorders0/1164/533/534/66
NasopharyngitisInfections and infestations2/1163/533/533/66
CoughRespiratory, thoracic and mediastinal disorders0/1161/533/531/66
DiarrhoeaGastrointestinal disorders1/1160/532/531/66
Upper respiratory tract infectionInfections and infestations0/1160/532/532/66
TonsillitisInfections and infestations1/1161/530/530/66
Exanthema subitumInfections and infestations0/1161/530/530/66
Herpes virus infectionInfections and infestations0/1161/530/531/66
PharyngitisInfections and infestations0/1161/530/531/66
RhinitisInfections and infestations0/1160/531/530/66

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Overall
Mean4.8 ± 2.58
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female63
Male60
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Overall
Chinese118
Other5
08

Study locations

4 sites
  • GSK Investigational Site
    Shenzhen, Guangdong 518038, China
  • GSK Investigational Site
    Changsha, Hunan 410007, China
  • GSK Investigational Site
    Beijing, China
  • GSK Investigational Site
    Shanghai, 200092, China
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Feb 2015, 13 months.

Results were first posted in Dec 2015, 10 months after primary completion.

Of 13 phase 4 interventional studies under Skin Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2013
First posted
Aug 5, 2013
StartActual
Dec 23, 2013
Primary completionActual
Feb 15, 2015
CompletionActual
Feb 15, 2015
Results first posted
Dec 23, 2015
Last update
Oct 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01915914
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 5, 2013
Start date
Dec 23, 2013
Primary completion
Feb 15, 2015
Completion
Feb 15, 2015
Results posted
Dec 23, 2015
Last update
Oct 12, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion